These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 27742728

  • 1. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
    Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, Engel SS, Lopes RD, McGuire DK, Riefflin A, Rodbard HW, Sinay I, Tankova T, Wainstein J, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Care; 2016 Dec; 39(12):2304-2310. PubMed ID: 27742728
    [Abstract] [Full Text] [Related]

  • 2. Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.
    Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Obes Metab; 2017 Nov; 19(11):1587-1593. PubMed ID: 28432745
    [Abstract] [Full Text] [Related]

  • 3. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
    Perkovic V, Toto R, Cooper ME, Mann JFE, Rosenstock J, McGuire DK, Kahn SE, Marx N, Alexander JH, Zinman B, Pfarr E, Schnaidt S, Meinicke T, von Eynatten M, George JT, Johansen OE, Wanner C, CARMELINA investigators.
    Diabetes Care; 2020 Aug; 43(8):1803-1812. PubMed ID: 32444457
    [Abstract] [Full Text] [Related]

  • 4. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR, TECOS Executive Committee.
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [Abstract] [Full Text] [Related]

  • 5. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
    McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED, Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group.
    JAMA Cardiol; 2016 May 01; 1(2):126-35. PubMed ID: 27437883
    [Abstract] [Full Text] [Related]

  • 6. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
    Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA® investigators.
    Cardiovasc Diabetol; 2018 Mar 14; 17(1):39. PubMed ID: 29540217
    [Abstract] [Full Text] [Related]

  • 7. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
    Nauck MA, McGuire DK, Pieper KS, Lokhnygina Y, Strandberg TE, Riefflin A, Delibasi T, Peterson ED, White HD, Scott R, Holman RR.
    Cardiovasc Diabetol; 2019 Sep 03; 18(1):116. PubMed ID: 31481069
    [Abstract] [Full Text] [Related]

  • 8. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
    Wexler DJ, de Boer IH, Ghosh A, Younes N, Bebu I, Inzucchi SE, McGill JB, Mudaliar S, Schade D, Steffes MW, Tamborlane WV, Tan MH, Ismail-Beigi F, GRADE Research Group.
    JAMA Intern Med; 2023 Jul 01; 183(7):705-714. PubMed ID: 37213109
    [Abstract] [Full Text] [Related]

  • 9. The kidney and cardiovascular outcome trials.
    Bloomgarden Z.
    J Diabetes; 2018 Feb 01; 10(2):88-89. PubMed ID: 29031006
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
    Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V.
    Circulation; 2018 Oct 09; 138(15):1537-1550. PubMed ID: 29941478
    [Abstract] [Full Text] [Related]

  • 11. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.
    Huang H, Shetty S, Bauer E, Lang K.
    Curr Med Res Opin; 2018 Jun 09; 34(6):1021-1027. PubMed ID: 29231750
    [Abstract] [Full Text] [Related]

  • 12. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B, EMPA-REG OUTCOME Investigators.
    Circulation; 2018 Jan 09; 137(2):119-129. PubMed ID: 28904068
    [Abstract] [Full Text] [Related]

  • 13. [TECOS: confirmation of the cardiovascular safety of sitaliptin].
    Scheen AJ, Paquot N.
    Rev Med Liege; 2015 Oct 09; 70(10):511-6. PubMed ID: 26727841
    [Abstract] [Full Text] [Related]

  • 14. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY, Yoon SA, Han BG, Kim SG, Jo YI, Jeong KH, Oh KH, Park HC, Park SH, Kang SW, Na KR, Kang SW, Kim NH, Jang Y, Kim B, Shin S, Cha DR.
    Diabetes Obes Metab; 2018 Feb 09; 20(2):292-300. PubMed ID: 28719008
    [Abstract] [Full Text] [Related]

  • 15. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
    Chen DY, Wang SH, Mao CT, Tsai ML, Lin YS, Chou CC, Wen MS, Wang CC, Hsieh IC, Hung KC, Chen TH.
    Int J Cardiol; 2015 Feb 15; 181():200-6. PubMed ID: 25528312
    [Abstract] [Full Text] [Related]

  • 16. Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD.
    Muanda FT, Weir MA, Bathini L, Clemens KK, Perkovic V, Sood MM, McArthur E, Sontrop JM, Kim RB, Garg AX.
    Clin J Am Soc Nephrol; 2020 Dec 07; 15(12):1728-1739. PubMed ID: 33239410
    [Abstract] [Full Text] [Related]

  • 17. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
    Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, Califf RM, Holman RR.
    Am Heart J; 2013 Dec 07; 166(6):983-989.e7. PubMed ID: 24268212
    [Abstract] [Full Text] [Related]

  • 18. Sitagliptin for Type 2 diabetes: a 2015 update.
    Lee M, Rhee MK.
    Expert Rev Cardiovasc Ther; 2015 Jun 07; 13(6):597-610. PubMed ID: 26000559
    [Abstract] [Full Text] [Related]

  • 19. Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.
    Standl E, Stevens SR, Armstrong PW, Buse JB, Chan JCN, Green JB, Lachin JM, Scheen A, Travert F, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Care; 2018 Mar 07; 41(3):596-603. PubMed ID: 29311155
    [Abstract] [Full Text] [Related]

  • 20. Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Reed SD, Li Y, Leal J, Radican L, Adler AI, Alfredsson J, Buse JB, Green JB, Kaufman KD, Riefflin A, Van de Werf F, Peterson ED, Gray AM, Holman RR, TECOS Study Group.
    Diabetes Obes Metab; 2018 Jul 07; 20(7):1732-1739. PubMed ID: 29573215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.